- Home
- CRVS vs FLOC Comparison
CRVS vs FLOC Comparison
Compare CRVS & FLOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- FLOC
- Stock Information
- Founded
- CRVS 2014
- FLOC 1996
- Country
- CRVS United States
- FLOC United States
- Employees
- CRVS N/A
- FLOC N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- FLOC Metal Fabrications
- Sector
- CRVS Health Care
- FLOC Industrials
- Exchange
- CRVS Nasdaq
- FLOC Nasdaq
- Market Cap
- CRVS 459.0M
- FLOC 417.7M
- IPO Year
- CRVS 2016
- FLOC 2025
- Fundamental
- Price
- CRVS $8.04
- FLOC $16.20
- Analyst Decision
- CRVS Strong Buy
- FLOC Strong Buy
- Analyst Count
- CRVS 4
- FLOC 6
- Target Price
- CRVS $13.75
- FLOC $30.17
- AVG Volume (30 Days)
- CRVS 1.1M
- FLOC 403.6K
- Earning Date
- CRVS 11-04-2025
- FLOC 11-05-2025
- Dividend Yield
- CRVS N/A
- FLOC 1.98%
- EPS Growth
- CRVS N/A
- FLOC N/A
- EPS
- CRVS N/A
- FLOC 3.01
- Revenue
- CRVS N/A
- FLOC $760,923,000.00
- Revenue This Year
- CRVS N/A
- FLOC $47.57
- Revenue Next Year
- CRVS N/A
- FLOC $8.16
- P/E Ratio
- CRVS N/A
- FLOC $5.38
- Revenue Growth
- CRVS N/A
- FLOC 155.05
- 52 Week Low
- CRVS $2.54
- FLOC $14.03
- 52 Week High
- CRVS $10.00
- FLOC $30.50
- Technical
- Relative Strength Index (RSI)
- CRVS 64.17
- FLOC 57.36
- Support Level
- CRVS $7.46
- FLOC $15.17
- Resistance Level
- CRVS $7.96
- FLOC $16.37
- Average True Range (ATR)
- CRVS 0.56
- FLOC 0.63
- MACD
- CRVS 0.01
- FLOC 0.16
- Stochastic Oscillator
- CRVS 75.46
- FLOC 92.64
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About FLOC Flowco Holdings Inc. Class A Common Stock
Flowco Holdings Inc is a provider of production optimization, artificial lift and methane abatement solutions for the oil and natural gas industry. Its technologies include high pressure gas lift (HPGL), conventional gas lift, plunger lift and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions which include rental services and Natural Gas Technologies which include service gas compression parts and equipment sales. Production Solutions: relates to rentals, sales and services related to high pressure gas lift, conventional gas lift and plunger lift; including other digital solutions and methane abatement technologies, and has maximum revenue.